Axonics ModulationTechnologies Inc

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axonics reports record Q4 revenue, eyes global expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q4 2022, with record revenue, solid margins, and profitability, while reiterating revenue guidance for 2023.
The company's focus on innovation, market leadership in sacral neuromodulation, and global expansion plans position it well for future growth despite challenges in international markets and legal uncertainties.
Opportunities in the U.S. and Asian markets, coupled with strategic initiatives like direct-to-consumer campaigns and product enhancements, offer avenues for sustained revenue growth and market dominance.

Axonics reports robust Q1 earnings, eyes market expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q1 2023, driven by revenue growth, operational efficiency, and strategic guidance updates for FY 2023.
The company's strengths lie in its robust commercial team, successful marketing campaigns, focus on innovation, and leadership's commitment to disciplined growth strategies.
While facing challenges such as legal uncertainties, coverage limitations, and margin management, Axonics has opportunities for market expansion, acquisitions, and technology advancements.
Overall, Axonics' performance, strengths, challenges, and opportunities position the company for continued growth and market leadership in the neuromodulation industry.

Axonics Modulation Technologies Reports Record Q2 Revenue Growth

Axonics Modulation Technologies delivered a strong performance in Q2, driven by revenue growth and operational efficiency.
The company's strengths lie in international expansion, robust commercial efforts, and continuous product innovation.
Challenges include legal uncertainties, market dynamics, and strategic positioning in a competitive landscape.
Opportunities for growth include market expansion, rising adoption trends, and enhancing customer experience.

Axonics reports robust Q3 earnings, eyes growth through innovation

Axonics delivered strong financial performance, driven by SNM and Bulkamid revenue growth and improved margins.
The company's focus on innovation, customer feedback, and market leadership positions it well for future growth.
Challenges include maintaining growth momentum, high rep productivity, and balancing marketing strategies.
Opportunities lie in expanding product offerings, market share, and leveraging direct-to-consumer campaigns for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company's sacral neuromodulation technology. The patents and allowed applications are part of Axonics' patent portfolio an

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the exercise in full by the underwriter of its option to purchase 262,500 additional shares. The gross proceeds from the offe

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Stock

Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it priced its previously announced underwritten public offering of 1,750,000 shares of its common stock. The offering is expected to close on August 5, 2022, subject to the satisfaction of customary closing conditions. Axonics has granted the underwriter a 30-d

Axonics® Announces Pricing of Public Offering of Common Stock

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed underwritten public offering of 1,750,000 shares of its common stock. Axonics expects to grant the underwriter a 30-day option to purchase up to an additional 262,500 shares of its common stock. Axonics anticipates using the net proc

Axonics® Announces Proposed Public Offering of Common Stock

Axonics, Inc. (NASDAQ:AXNX ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Adam Maeder - Piper Sandler Cecilia Furlong - Morgan Stanley Lawrence Biegelsen - Wells Fargo Securities Mike Polark - Wolfe Research Mike Matson - Needham & Company Operator Good day and thank you for standing by. Welcome to the Axonics Q2 2022 Results Conference Call.

Axonics, Inc. (AXNX) CEO Raymond Cohen on Q2 2022 Results - Earnings Call Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2022. “This quarter's record revenue result reflects the growing demand for our best-in-class incontinence solutions,” said Raymond W. Cohen, chief executive officer of Axonics. “Sacral neuromodulation revenue grew 39% year o

Axonics® Reports Second Quarter 2022 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties that would like to join the conference call by telephone are required to register in

Axonics® to Report Second Quarter 2022 Financial Results on August 1

Outset Medical

Omnicell

Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.

3 Medical Info System Stocks Braving Industry Headwinds

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulation implantable neurostimulator (INS). The fourth generation rechargeable INS reduces how frequently a patient needs to recharge their implanted device to only once every six months

Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

Axonics is a high-growth medical device play with strong revenue growth drivers. The company's rechargeable SNM system generates the vast majority of its sales.

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

Axonics, Inc. (NASDAQ:AXNX ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Cecilia Furlong - Morgan Stanley Mike Matson - Needham & Company David Rescott - Truist Securities Michael Polark - Wolfe Research Priya Sachdeva - SVB Securities Operator Good day. Thank you for standing by.

Axonics, Inc. (AXNX) CEO Raymond Cohen on Q1 2022 Results - Earnings Call Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. “We are pleased with this quarter's revenue result considering the significant impact the Omicron surge had on elective procedures in January and February,” said Raymond W. Cohen, chief executive officer of Axonics. “S

Axonics® Reports First Quarter 2022 Financial Results

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out for

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022. Axonics is scheduled to present at 12:20 p.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website. About Axonics Based in Irvine, Ca

Axonics® to Participate in BofA Securities 2022 Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system received FDA approval in March. “The Axonics recharge-free system is a welcome advancement for patients suffering from

Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217-87

Axonics® to Report First Quarter 2022 Financial Results on May 5

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign. The Find Real Relief campaign is focused on women with any form of urinary incontinence, a large and significantly undertreated population. The campaign aims to reduce the stigma associated with these conditi

Axonics® Launches Direct to Consumer Television Advertising Campaign

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). The Axonics F15™ recharge-free SNM system has the following key attributes: INS type: primary cell batter

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

Axonics, Inc. (AXNX) CEO Raymond Cohen on Q4 2021 Results - Earnings Call Transcript

Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2021. “We are proud of our fourth quarter and fiscal year 2021 results considering the disruption Covid-19 has had on elective procedures in the U.S. and around the world,” said Raymond W. Cohen, chief exe

Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Earnings Preview: Axonics Modulation Technologies (AXNX) Q4 Earnings Expected to Decline

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-57

News for Axonics ModulationTechnologies Inc Stock (AXNX)